New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting interesting chapters on a variety of important topics, including Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.
1. Cover image - p. i 2. Table of Contents - p. iii 3. Series Page - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Chapter One: Current innovative engineered antibodies - p. 9 7. Chapter Two: Opportunities and challenges of bi-specific antibodies - p. 45 8. Chapter Three: Applications of trimerbodies in cancer immunotherapy - p. 71 9. Chapter Four: Anticalin®-based therapeutics: Expanding new frontiers in drug development - p. 89 10. Chapter Five: Overcoming the limitations of cytokines to improve cancer therapy - p. 118 11. Chapter Six: Emerging applications of nanobodies in cancer therapy - p. 152
New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting interesting chapters on a variety of important topics, including Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.
1. Cover image - p. i 2. Table of Contents - p. iii 3. Series Page - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Chapter One: Current innovative engineered antibodies - p. 9 7. Chapter Two: Opportunities and challenges of bi-specific antibodies - p. 45 8. Chapter Three: Applications of trimerbodies in cancer immunotherapy - p. 71 9. Chapter Four: Anticalin®-based therapeutics: Expanding new frontiers in drug development - p. 89 10. Chapter Five: Overcoming the limitations of cytokines to improve cancer therapy - p. 118 11. Chapter Six: Emerging applications of nanobodies in cancer therapy - p. 152
